Royalty Pharma (RPRX) - EPS (earnings per share)

EPS in 2023 (TTM): HK$4.35

According to Royalty Pharma's latest financial reports the company's current EPS (TTM) is HK$14.71. In 2022 the company made an earnings per share (EPS) of HK$0.78 a decrease over its 2021 EPS that were of HK$11.76.

EPS history for Royalty Pharma from 2019 to 2023

Annual EPS

Year	EPS	Change
2023 (TTM)	HK$4.35	454.54%
2022	HK$0.78	-93.33%
2021	HK$11.76	-1.33%
2020	HK$11.92	-77.07%
2019	HK$52.00

EPS for similar companies or competitors

Company	EPS	EPS differencediff.	Country
Abbott Laboratories ABT	HK$21.21	44.17%	🇺🇸 USA
Eli Lilly LLY	HK$242.04	1,545.44%	🇺🇸 USA
ANI Pharmaceuticals ANIP	HK$37.87	157.48%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

EPS for Royalty Pharma (RPRX)

EPS in 2023 (TTM): HK$4.35